Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. (CAI) from its SEC filings: 2025 revenue $812.0 million (+97% vs the year before), net margin -8%, free cash flow $66.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories |
| Revenue (2025) | $812.0 million |
| Revenue growth | +97% |
| Net income | -$68.1 million |
| Net margin | -8.4% |
| Free cash flow | $66.9 million |
| Diluted EPS | $-3.22 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +45% |
| Cash | $819.9 million |
| Long-term debt | $393.0 million |
| Share count, 1 year | +0% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.